NCT00896571View on ClinicalTrials.gov

Transdermal Contraceptive Patch - Endometrial Effects Study

PHASE2CompletedINTERVENTIONAL

Enrollment

92

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

May 31, 2011

Study Completion Date

August 31, 2011

Conditions

Contraception

Interventions

DRUG

Ethinylestradiol/Gestogene (BAY86-5016)

7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen

Trial Locations (1)

10629

Berlin

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY

NCT00896571 - Transdermal Contraceptive Patch - Endometrial Effects Study | Biotech Hunter | Biotech Hunter